StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Emgality (galcanezumab) by Quarter

Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy] (%)

QuarterlyAnnual

Eli Lilly Emgality (galcanezumab): 20.0% in Q3 2024, down 34.6 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2024
20.0%
Period ended Sep 30, 2024
Change on a year earlier
-34.6 pts
54.6% in Q3 2023
History
17 quarters
Since Q3 2020
Sources
17
Documents cited below

Where the Q3 2024 figure comes from

“|| Emgality ® | 141.3 | 61.6 | 202.9 | 168.5 | 20”

Source: Form 10-Q FY2024Q3 (filed 2024-10-30) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEmgality (galcanezumab) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 202420.0%-34.6 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 202413.0%+5.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 202446.0%+43.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q4 2023Dec 31, 20236.0%-3.0 ptsEarnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 202354.6%+34.6 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 20238.0%+7.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 20233.0%-22.0 ptsForm 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q4 2022Dec 31, 20229.0%-38.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 202220.0%-33.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 20221.0%-78.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 202225.0%-36.0 ptsForm 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q4 2021Dec 31, 202147.0%-19.0 ptsEarnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗
Q3 2021Sep 30, 202153.0%-39.0 ptsForm 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 202179.0%–Form 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 202161.0%–Form 10-Q FY2021Q1 (filed 2021-04-30) ↗
Q4 2020Dec 31, 202066.0%–Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗

Cite this data

StockData. (2026). Eli Lilly Emgality (galcanezumab) (%), quarterly Q3 2020–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-emgality-yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.